Antiangiogenic effects of butyric acid involve inhibition of VEGF/KDR gene expression and endothelial cell proliferation

被引:31
作者
Gururaj, AE
Belakavadi, M
Salimath, BP [1 ]
机构
[1] Univ Mysore, Dept Appl Bot & Biotechnol, Mysore 570006, Karnataka, India
[2] Univ Mysore, Dept Biochem, Mysore, Karnataka, India
关键词
butyrate; endothelial cells; apoptosis; angiogenic ligand-receptor; gene expression; antiangiogenesis;
D O I
10.1023/A:1021647726366
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The formation of new blood vessels from pre-existing ones is required for the growth of solid tumors and for metastasis. Interaction of tumor-secreted vascular endothelial growth factor (VEGF) with its receptor(s) on endothelial cells triggers endothelial cell proliferation and migration, which facilitate tumor angiogenesis. Butyric acid (BuA), a fermentation product of dietary fibers in the colon, is shown to alter gene expression and is postulated to be anticarcinogenic. The results presented in this paper indicate that BuA can be antiangiogenic in vivo by inhibiting angiogenesis in chorioallantoic membrane assay. BuA was not cytotoxic to endothelial cells but was a potent antiproliferative agent besides being proapoptotic to endothelial cells as verified by FACS analysis. Conditioned media from BuA-treated Ehrlich ascites tumor cells showed a 30% decrease in VEGF concentration when compared with untreated cells. The decrease in VEGF mRNA and its receptor, KDR mRNA levels in EAT and endothelial cells respectively, suggests that the VEGF-KDR system of angiogenesis is the molecular target for the antiangiogenic action of BuA.
引用
收藏
页码:107 / 112
页数:6
相关论文
共 25 条
[1]  
CALEBRESSE C, 1994, BIOCHEM BIOPH RES CO, V201, P266
[2]   Kringle domains of human angiostatin - Characterization of the anti-proliferative activity on endothelial cells [J].
Cao, YH ;
Ji, RW ;
Davidson, D ;
Schaller, J ;
Marti, D ;
Sohndel, S ;
McCance, SG ;
OReilly, MS ;
Llinas, M ;
Folkman, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (46) :29461-29467
[3]   INHIBITION OF CAPILLARY MORPHOGENESIS AND ASSOCIATED APOPTOSIS BY DOMINANT-NEGATIVE MUTANT TRANSFORMING GROWTH-FACTOR-BETA RECEPTORS [J].
CHOI, ME ;
BALLERMANN, BJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (36) :21144-21150
[4]   Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate [J].
Dangond, F ;
Gullans, SR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 247 (03) :833-837
[5]   DISTRIBUTION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) IN TUMORS - CONCENTRATION IN TUMOR BLOOD-VESSELS [J].
DVORAK, HF ;
SIOUSSAT, TM ;
BROWN, LF ;
BERSE, B ;
NAGY, JA ;
SOTREL, A ;
MANSEAU, EJ ;
VANDEWATER, L ;
SENGER, DR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (05) :1275-1278
[6]   The role of apoptosis in wound healing [J].
Greenhalgh, DG .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1998, 30 (09) :1019-1030
[7]  
Guo NH, 1997, CANCER RES, V57, P1735
[8]   SYNTHETIC ANALOGS OF FUMAGILLIN THAT INHIBIT ANGIOGENESIS AND SUPPRESS TUMOR-GROWTH [J].
INGBER, D ;
FUJITA, T ;
KISHIMOTO, S ;
SUDO, K ;
KANAMARU, T ;
BREM, H ;
FOLKMAN, J .
NATURE, 1990, 348 (6301) :555-557
[9]  
KIESER A, 1994, ONCOGENE, V9, P963
[10]   SIGNIFICANCE OF VASCULAR ENDOTHELIAL GROWTH-FACTOR VASCULAR-PERMEABILITY FACTOR FOR SOLID TUMOR-GROWTH, AND ITS INHIBITION BY THE ANTIBODY [J].
KONDO, S ;
ASANO, M ;
SUZUKI, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 194 (03) :1234-1241